TransCode Therapeutics to Participate at BIO International Convention

Rhea-AI Summary

BOSTON, June 09, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics (Nasdaq: RNAZ) announced its attendance and presentation at the BIO International Convention from June 13-16, 2022, in San Diego, CA. CEO Michael Dudley will discuss the company’s RNA-based scientific discoveries that could significantly enhance cancer treatment. He will also outline plans for the lead candidate, TTX-MC138, aimed at treating metastatic disease and progressing to its First-in-Human clinical trial.

BOSTON, June 09, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the BIO International Convention to be held June 13-16 in San Diego, CA. The in-person venue for the event is the San Diego Convention Center.

During the presentation, TransCode’s Chief Executive Officer, Michael Dudley, will discuss the Company's RNA-based scientific discoveries that it believes have the potential to significantly advance the treatment of cancer. Dudley will also describe the Company’s plans to advance its lead therapeutic candidate, TTX-MC138, designed to treat metastatic disease, into its First-in-Human clinical trial. 

	Event:	BIO International Convention
	Date:	June 13-16, 2022
	Presentation:	June 13, 2022, at 2:30 PM (PT)
	Convention:	https://www.bio.org/events/bio-international-convention/sessions/881957

About TransCode Therapeutics

TransCode is an RNA oncology company created on the belief that cancer can be defeated using RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which is believed to cause approximately 90% of all cancer deaths totaling over nine million per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. Two of the Company’s other drug candidates, TTX-siPDL1 and TTX-siLIN28B, focus on treating tumors by targeting PD-L1 and LIN28B, respectively. TransCode also has three cancer-agnostic programs: TTX-RIGA, an RNA–based agonist of the retinoic acid-inducible gene I, or RIG-I, approach designed to drive an immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines designed to activate cytotoxic immune responses against tumor cells.

Forward-looking Statement

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning the potential for treating cancer with RNA therapeutics, statements concerning the timing and outcome of expected regulatory filings and clinical trials, including the filing of an eIND for the planned first-in-human study of TTX-MC138, statements concerning the timing and outcome of this study, including whether this study will demonstrate proof-of-mechanism, statements concerning patent applications, and statements concerning TransCode’s development programs and TTX technology platform generally. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk associated with drug discovery and development; the risk that the results of our planned clinical trials will not be consistent with our pre-clinical studies or expectations; risks associated with the timing and outcome of TransCode’s planned regulatory submissions; risks associated with TransCode’s planned clinical trials for its product candidates; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with TransCode’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; the risk of competition from other companies developing products for similar uses; risks associated with TransCode’s financial condition and its need to obtain additional funding to support its business activities, including TransCode’s ability to continue as a going concern; risks associated with TransCode’s dependence on third parties; and risks associated with the COVID-19 coronavirus. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause TransCode’s actual results to differ from those contained in or implied by the forward-looking statements, see the section entitled “Risk Factors” in TransCode’s Annual Report on Form 10-K for the year ended December 31, 2021, as well as discussions of potential risks, uncertainties and other important factors in any subsequent TransCode filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release; TransCode undertakes no duty to update this information unless required by law.

For more information, please contact:

TransCode Therapeutics, Inc.
Alan Freidman, VP Investor Relations
alan.freidman@transcodetherapeutics.com

Dave Gentry, CEO
RedChip Companies
Office: 1.800.RED.CHIP (733.2447)
Cell: 407.491.4498
RNAZ@redchip.com

FAQ

What is TransCode Therapeutics presenting at the BIO International Convention?

TransCode Therapeutics will present its RNA-based discoveries and discuss plans for its lead candidate, TTX-MC138, targeting metastatic cancer.

When is TransCode's presentation at the BIO International Convention?

TransCode's presentation is scheduled for June 13, 2022, at 2:30 PM (PT).

Where is the BIO International Convention being held?

The BIO International Convention is being held at the San Diego Convention Center in San Diego, CA.

What is the significance of TTX-MC138 in cancer treatment?

TTX-MC138 is designed to treat metastatic cancer and is intended to progress into First-in-Human clinical trials.

What are the potential benefits of RNA therapeutics according to TransCode?

TransCode believes RNA therapeutics can significantly improve cancer treatment outcomes and potentially lead to regression without recurrence.